Peter J Barnes Selected Research

Chronic Obstructive Pulmonary Disease (COPD)

06/2008	Frontrunners in novel pharmacotherapy of COPD.
01/2008	CXCR3 and CCR5 Chemokines in Induced Sputum From Patients With COPD.
09/2007	Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.
05/2007	Unexpected failure of anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease.
04/2007	Normal bronchial blood flow in COPD is unaffected by inhaled corticosteroids and correlates with exhaled nitric oxide.
10/2006	Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease.
07/2006	Pulmonary biomarkers in chronic obstructive pulmonary disease.
02/2006	Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease.
01/2006	Reduced histone deacetylase in COPD: clinical implications.
12/2005	Targeting histone deacetylase 2 in chronic obstructive pulmonary disease treatment.
05/2005	Decreased histone deacetylase activity in chronic obstructive pulmonary disease.
01/2005	Theophylline in chronic obstructive pulmonary disease: new horizons.
12/2004	The role of anticholinergics in chronic obstructive pulmonary disease.
09/2004	Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages.
08/2004	Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2.
02/2004	Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase.
01/2004	Effects of corticosteroids on noninvasive biomarkers of inflammation in asthma and chronic obstructive pulmonary disease.
01/2004	Theophylline: mechanism of action and use in asthma and chronic obstructive pulmonary disease.
12/2003	High levels of interleukin-6 in the exhaled breath condensate of patients with COPD.
06/2003	Long-acting beta 2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified?
04/2003	Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4.
03/2003	Nitric oxide, nitrotyrosine, and nitric oxide modulators in asthma and chronic obstructive pulmonary disease.
01/2003	Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease.
09/2002	Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD.
06/2002	Effect of dopamine receptor agonists on sensory nerve activity: possible therapeutic targets for the treatment of asthma and COPD.
05/2002	Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease.
05/2002	Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease.

Articles by Research Topic

Disease

34	Asthma (Bronchial Asthma) 10/2008 - 03/2002
27	Chronic Obstructive Pulmonary Disease (COPD) 06/2008 - 05/2002
4	Inflammation 06/2006 - 09/2002
3	Cough 01/2007 - 09/2003
2	Lung Diseases (Lung Disease) 12/2005 - 01/2002
2	Obstructive Sleep Apnea 10/2003 - 10/2002
2	Cystic Fibrosis (Mucoviscidosis) 04/2003 - 02/2002
1	Dyspnea (Shortness of Breath) 10/2005
1	Kartagener Syndrome (Primary Ciliary Dyskinesia) 08/2003
1	Anoxia (Hypoxia) 03/2002
1	Pulmonary Hypertension (Ayerza Syndrome) 03/2002

Drug/Important Bio-Agent (IBA)

7	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2007 - 09/2002
6	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2007 - 11/2002
5	8-epi-prostaglandin F2alphaIBA 01/2005 - 08/2002
4	LeukotrienesIBA 01/2006 - 04/2002
4	Histone Deacetylases (Histone Deacetylase)IBA 01/2006 - 02/2004
4	Theophylline (Theon)FDA LinkGeneric 01/2005 - 05/2002
3	formoterol (Oxis)FDA Link 09/2007 - 05/2002
3	Biological Markers (Surrogate Marker)IBA 07/2006 - 01/2002
3	Interleukin-6 (Interleukin 6)IBA 12/2003 - 10/2002
2	ciclesonide FDA Link 10/2008 - 06/2006
2	Budesonide (Pulmicort)FDA LinkGeneric 09/2007 - 06/2006
2	Interleukin-8 (Interleukin 8)IBA 07/2007 - 04/2003
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2007 - 10/2006
2	ProstaglandinsIBA 08/2006 - 04/2002
2	tiotropium (Spiriva)FDA Link 06/2003 - 09/2002
2	Leukotriene B4IBA 04/2003 - 04/2003
2	Matrix Metalloproteinase 9 (Gelatinase B)IBA 11/2002 - 05/2002
1	CVT 3146 FDA Link 05/2008
1	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 05/2008
1	ChemokinesIBA 01/2008
1	montelukast (Singulair)FDA Link 12/2007
1	GoldIBA 09/2007
1	Antitussive Agents (Antitussives)IBA 01/2007
1	Chemokine ReceptorsIBA 10/2006
1	Leukotriene Receptors (Leukotriene Receptor)IBA 08/2006
1	Leukotriene E4IBA 08/2006
1	Purinergic P1 Receptors (Adenosine Receptor)IBA 02/2006
1	Histones (Histone)IBA 12/2005
1	histone deacetylase-2IBA 12/2005
1	Glycopyrrolate (Glycopyrronium Bromide)FDA LinkGeneric 10/2005
1	Adenosine FDA LinkGeneric 10/2005
1	TheobromineIBA 02/2005
1	Cholinergic Antagonists (Anticholinergics)IBA 12/2004
1	ChitinaseIBA 10/2004
1	CC ChemokinesIBA 08/2004
1	Histone Acetyltransferases (Histone Acetyltransferase)IBA 07/2004
1	CB2 Cannabinoid ReceptorIBA 09/2003
1	Immunoglobulin E (IgE)IBA 06/2003
1	3-nitrotyrosineIBA 03/2003
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2003
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 08/2002
1	Dopamine Agonists (Dopamine Agonist)IBA 06/2002
1	Interferon-gamma (Interferon, gamma)IBA 05/2002
1	salmeterol (Serevent)FDA Link 05/2002
1	Tissue Inhibitor of Metalloproteinase-1IBA 05/2002
1	Interleukin-4 (Interleukin 4)IBA 05/2002
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 04/2002
1	Protein Kinases (Protein Kinase)IBA 04/2002
1	Adrenergic Receptors (Adrenergic Receptor)IBA 03/2002
1	Interleukin-12 (IL 12)IBA 03/2002
1	Interleukin-10 (Interleukin 10)IBA 03/2002
1	G-Protein-Coupled Receptor KinasesIBA 02/2002

Therapy/Procedure

2	Nebulizers and Vaporizers (Inhaler) 09/2007 - 01/2005
1	Drug Therapy (Chemotherapy) 06/2008
1	Continuous Positive Airway Pressure 10/2003